The impact of FDA regulatory activities on incident dispensing of LABA-containing medication: 2005–2011

References

• Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993;306(6884):1034–1037.
   PubMedGoogle Scholar
• Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF Jr, Sorkness CA, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001;285:2583–2593.
   PubMed Web of Science ®Google Scholar
• Lemanske RF Jr, Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Fahy JV, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 2001;285:2594–2603.
   PubMed Web of Science ®Google Scholar
• Mann M, Chowdhury B, Sullivan E, Nicklas R, Anthracite R, Meyer RJ. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003;124:70–74.
   PubMed Web of Science ®Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129(1):15–26.
   PubMed Web of Science ®Google Scholar
• FDA. 2005. Pulmonary-Allergy Drugs Advisory Committee (PADAC) Meeting. Available from: http://www.fda.gov/ohrms/dockets/ac/cder05.html#PulmonaryAllergy [last assessed 11 August 2016].
   Google Scholar
• FDA Public Health Advisory. Previous Safety Communications, 2005–2006 [ARCHIVED]. Available from: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm199565.htm [last accessed 11 August 2016].
   Google Scholar
• FDA Drug Safety Communication. Safety Information for Consumers and Healthcare Professionals. 2010; Available from: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm199565.htm [last accessed 11 August 2016].
   Google Scholar
• Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. Developing the sentinel system – a national resource for evidence development. N Engl J Med 2011;364:498–499.
   PubMed Web of Science ®Google Scholar
• Platt R, Carnahan RM, Brown JS, Chrischilles E, Curtis LH, Hennessy S, et al. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf 2012;21(Suppl 1):1–8.
   PubMedGoogle Scholar
• Butler MG, Zhou EH, Zhang F, Wu YT, Wu AC, Levenson MS, et al. Changing patterns of asthma medication use related to US Food and Drug Administration long-acting β2-agonist regulation from 2005–2011. J Allergy Clin Immunol 2016;137(3):710–717.
   PubMed Web of Science ®Google Scholar
• Prosser RJ, Carleton BC, Smith MA. Identifying persons with treated asthma using administrative data via latent class modelling. Health Serv Res 2008;43(2):733–754.
   PubMed Web of Science ®Google Scholar
• Blanchette CM, Culler SD, Ershoff D, Gutierrez B. Association between previous health care use and initiation of inhaled corticosteroid and long-acting beta2-adrenergic agonist combination therapy among US patients with asthma. Clin Ther 2009;31(11):2574–2583.
   PubMed Web of Science ®Google Scholar
• Thomas M, Murray-Thomas T, Fan T, Williams T, Taylor S. Prescribing patterns of asthma controller therapy for children in UK primary care: a cross-sectional observational study. BMC Pulm Med 2010;10:29.
   PubMed Web of Science ®Google Scholar
• Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299–309.
   PubMed Web of Science ®Google Scholar
• Shadish WR. Experimental and quasi-experimental designs for generalized causal inference. Boston: Houghton Mifflin; 2002.
   Google Scholar
• Lu CY, Zhang F, Lakoma MD, Madden JM, Rusinak D, Penfold RB, et al. Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study. BMJ 2014;348:g3596.
   PubMedGoogle Scholar
• Collett D. Modelling survival data in medical research. 2nd ed. Boca Raton: Chapman & Hall/CRC; 2003; ISBN: 1584883251.
   Google Scholar
• Bobbit LG, Otto MC. Effects of forecasts on the revisions of seasonally adjusted data using the X-11 adjustment procedure. Proceedings of the Business and Economic Statistics Section of the American Statistical Association; 1990;449–453.
   Google Scholar
• National Heart Lung and Blood Institute NAEPP. 2007. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Available from: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf [last accessed 11 August 2016].
   Google Scholar
• Hartung DM, Middleton L, Markwardt S, Williamson K, Ketchum K. Changes in long-acting β-agonist utilization after the FDA's 2010 drug safety communication. Clin Ther 2015;37(1):114–123.
   PubMed Web of Science ®Google Scholar
• Zhou EH, Seymour S, Goulding MR, Kang EM, Major JM, Iyasu S. The US Food and Drug Administration's drug safety recommendations and long-acting beta2-agonist dispensing pattern changes in adult asthma patients: 2003–2012. J Asthma Allergy 2017;10:67–74.
   PubMed Web of Science ®Google Scholar
• Zhou EH, Kang EM, Seymour S, Iyasu S. Long-acting beta2-adrenergic agonist in pediatric and adolescent asthma patients, 2003–2011. J Asthma 2014;51(10):1061–1067.
   PubMed Web of Science ®Google Scholar
• Korelitz JJ, Zito JM, Gavin NI, Masters MN, McNally D, Irwin DE, et al. Asthma-related medication use among children in the United States. Ann Allergy Asthma Immunol 2008;100(3):222–229.
   PubMed Web of Science ®Google Scholar
• Kesselheim AS, Donneyong M, Dal Pan GJ, Zhou EH, Avorn J, Schneeweiss S, Seeger JD. Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. Pharmacoepidemiol Drug Saf 2017;26(6):712–21.
   PubMed Web of Science ®Google Scholar
• Cohen A, Rabbani A, Shah N, Alexander GC. Changes in glitazone use among office-based physicians in the U.S., 2003–2009. Diabetes Care 2010;33:823–825.
   PubMed Web of Science ®Google Scholar
• Kesselheim AS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, et al. Methodological approaches to evaluate the impact of FDA drug safety communications. Drug Saf 2015;38(6):565–575.
   PubMed Web of Science ®Google Scholar